{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+immunoglobulin+%28IVIG%29&page=3",
    "query": {
      "intervention": "Intravenous immunoglobulin (IVIG)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 221,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+immunoglobulin+%28IVIG%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+immunoglobulin+%28IVIG%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T07:02:02.384Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01350440",
      "title": "Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinocerebellar Ataxia"
      ],
      "interventions": [
        {
          "name": "IVIG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 5,
      "start_date": "2011-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-23",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350440"
    },
    {
      "nct_id": "NCT00986947",
      "title": "Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure"
      ],
      "interventions": [
        {
          "name": "IVIg and rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-09",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-01",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986947"
    },
    {
      "nct_id": "NCT03342638",
      "title": "Maximizing Outcome of Multiple Sclerosis Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "rATG",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "IVIg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Stem Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 66,
      "start_date": "2017-11-08",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03342638"
    },
    {
      "nct_id": "NCT07648264",
      "title": "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "IgPro20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2026-09-15",
      "completion_date": "2029-03-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 17,
      "location_summary": "Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07648264"
    },
    {
      "nct_id": "NCT06533098",
      "title": "A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombocytopenia, Neonatal Alloimmune"
      ],
      "interventions": [
        {
          "name": "Nipocalimab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulins (IVIG)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-02-10",
      "completion_date": "2029-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533098"
    },
    {
      "nct_id": "NCT01421212",
      "title": "Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B Virus Associated Liver Disease"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Immune Globulin (Boca HBVIg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biotest Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1999-11",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Gainesville, Florida • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421212"
    },
    {
      "nct_id": "NCT02810444",
      "title": "Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Disease"
      ],
      "interventions": [
        {
          "name": "IgG Next Generation (BT595)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biotest",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 81,
      "start_date": "2016-10-04",
      "completion_date": "2020-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Thornton",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02810444"
    },
    {
      "nct_id": "NCT00068055",
      "title": "IVIG - West Nile Encephalitis: Safety and Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "West Nile Virus"
      ],
      "interventions": [
        {
          "name": "Omr-lgG-am",
          "type": "DRUG"
        },
        {
          "name": "Polygam® S/D",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2003-09",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2011-02-07",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068055"
    },
    {
      "nct_id": "NCT05755035",
      "title": "A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "TAK-881",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2023-10-24",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 15,
      "location_summary": "Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755035"
    },
    {
      "nct_id": "NCT01628055",
      "title": "IVIG in Acute Ischemic Stroke: A Pilot Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Privigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-03",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-11",
      "last_synced_at": "2026-10-07T07:02:02.384Z",
      "location_count": 1,
      "location_summary": "Falls Church, Virginia",
      "locations": [
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01628055"
    }
  ]
}